| ISSN |
2307-8960 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Prospective Study |
| Article Title |
Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mortada HF El-Shabrawi, Laila M Sherief, Mostafa Yakoot, Naglaa M Kamal, Mohamed A Almalky, Manal M AbdElgawad, Aml A Mahfouz, Sherine Helmy, Enas Mohamed Kamal, Dina Attia and Hisham R El-Khayat |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mostafa Yakoot, MD, Chairman, Chief Doctor, Internal medicine, Pediatrics and Hepatology, Green Clinic and Research Center, Alexandria University, 27 Green Street, Alexandria 21121, Egypt, Egypt. yakoot@yahoo.com |
| Key Words |
Chronic hepatitis C; Survivors of childhood cancer; Sofosbuvir; Daclatasvir; Efficacy; |
| Core Tip |
Dual Sofosbuvir/Daclatasvir (SOF/DCV) treatment was found to be as effective in the treatment of chronic hepatitis C virus (HCV) in survivors of childhood hematologic malignancy as in others with no history of malignancy. No relapses detected during study for the original malignant disease or the HCV infection. The results of this study could be assuring that the treatment of chronic HCV infection with direct-acting antivirals (DAAs) might not adversely affect the state of remission of survivors of hematologic malignancy in pediatric age groups; though larger studies with different DAAs and longer follow up are needed to confirm. |
| Publish Date |
2019-08-26 02:56 |
| Citation |
El-Shabrawi MH, Sherief LM, Yakoot M, Kamal NM, Almalky MA, AbdElgawad MM, Mahfouz AA, Helmy S, Kamal EM, Attia D, El-Khayat HR. Effects of dual sofosbuvir/daclatasvir therapy on, chronic hepatitis C infected, survivors of childhood malignancy. World J Clin Cases 2019; 7(16): 2247-2255 |
| URL |
https://www.wjgnet.com/2307-8960/full/v7/i16/ 2247.htm |
| DOI |
https://dx.doi.org/10.12998/wjcc.v7.i16.2247 |
